FDA’s AI Risk-Based Guidance Shifts Validation Burden to Sponsors

This guidance matters as it defines accountability for AI risks in clinical trials, influencing safety and regulatory practices.

Auto-scored: Low risk from regulatory framing, but substantive mitigation through governance in AI medicine.